SCHEMBL2299376

SCHEMBL2299376

O=C(c1ccccc1)c1ccccc1OC(O)O.[NaH]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.53
ABCB1 P08183 7/20 0.50
AKR1C3 P42330 1/20 0.50
MAPT P10636 4/20 0.47
MAPK1 P28482 2/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 2/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DRD2 P14416 1/20 0.46
DRD1 P21728 1/20 0.46
DRD3 P35462 1/20 0.46
ALDH1A1 P00352 1/20 0.45
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
KMT2A Q03164 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770171 0.98 ELANE (0.54) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL31602130 0.98 ELANE (0.54) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL2299380 0.96 ELANE (0.53) ELANEABCB1AKR1C3MAPTMAPK1
Sulfuric Acid SCHEMBL18204474 0.94 ELANE (0.48) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL18204475 0.85 ELANE (0.43) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL2228864 0.84 ELANE (0.55) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL5073351 0.82 MAPT (0.54) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL27694472 0.82 IRAK4 (0.64) ELANEABCB1AKR1C3MAPTMAPK1
SCHEMBL30668163 0.82 MAPT (0.54) ELANEABCB1AKR1C3MAPTMAPK1
Acetic Acid SCHEMBL21549818 0.81 ELANE (0.53) ELANEABCB1AKR1C3MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025110244-A1 NOVEL COMPOUND AND USE THEREOF オリザ油化株式会社 2025-05-30 WO disclosed
CN-119968195-A Aqueous polymer emulsion for cosmetics, method for producing same, and cosmetics 东亚合成株式会社 2025-05-09 CN disclosed
US-20250082592-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-03-13 US disclosed
US-12221495-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide IGISU CO., LTD. (JP) 2025-02-11 US disclosed
WO-2024232390-A1 IRRITATION RELIEVING AGENT, PRODUCTION METHOD THEREOF AND SKIN EXTERNAL PREPARATION リファインホールディングス株式会社 2024-11-14 WO disclosed
US-20240358779-A1 EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA, AND USE THEREOF MD HEALTHCARE INC. (KR) 2024-10-31 US disclosed
WO-2024196194-A1 NOVEL ENTEROCOCCUS FAECALIS HL1 STRAIN AND USE THEREOF 재단법인 아산사회복지재단 2024-09-26 WO disclosed
CN-113924357-B Bifidobacterium longum strain or cosmetic composition comprising cell lysate of said strain 株式会社爱托健 2024-09-24 CN disclosed
WO-2024181594-A1 BROCCOLI SPROUT FERMENTATION METHOD TO INCREASE ACTIVE INGREDIENT CONTENT, AND BROCCOLI SPROUT POWDER PRODUCED THEREBY 주식회사 컴투네이처 2024-09-06 WO disclosed
US-12065512-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide IGISU CO., LTD. (JP) 2024-08-20 US disclosed
US-20100286093-A1 ANTI-INFLAMMATORY COMPOSITION CONTAINING DOCOSAHEXAENOYL LYSOPHOSPHATIDYLAMINE AS AN ACTIVE INGREDIENT THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) 2010-11-11 US disclosed
US-20100280231-A1 WHITENING AGENT COMPRISING EQUOL OR ITS SACCHARIDE DERIVATIVE AS AN EFFECTIVE INGREDIENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2010-11-04 US disclosed
EP-2145615-A1 SKIN-LIGHTENING AGENT CONTAINING EQUOL COMPOUND AS ACTIVE INGREDIENT Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) 2010-01-20 EP disclosed
US-20070231403-A1 Natural composite preservatives BIOSPECTRUM, INC. (KR) 2007-10-04 US disclosed
EP-0887070-B1 External composition for skin comprising sphingoglycolipid KIBUN FOOD CHEMIFA (JP) 2004-12-22 EP disclosed
US-6514744-B2 Skin moisturizer KIBUN FOOD CHEMIFA CO., LTD. (JP) 2003-02-04 US disclosed
US-20020164351-A1 External compositions for skin comprising sphingoglycolipid KIBUN FOOD CHEMIFA CO., LTD. (JP) 2002-11-07 US disclosed
US-6348201-B2 SPHINGOGLYCOLIPID AVAILABLE AS COSMETIC AND MEDICINE, HAS POTENT MOISTURIZING EFFEACT AND PREVENTIVE EFFECT AGAINST SKIN ROUGHNESS; SPHINOGGLYCOLIPID CONTAINING SUGAR MOITIES AND AMIDE GROUP KIBUN FOOD CHEMIFA CO., LTD. (JP) 2002-02-19 US disclosed
US-20020006414-A1 EXTERNAL COMPOSITION FOR SKIN COMPRISING SPHINGOGLYCOLIPID FOODCHEMIFA CO., LTD. (JP) 2002-01-17 US disclosed
EP-0887070-A1 External composition for skin comprising sphingoglycolipid Kibun Food ChemiFA Co., Ltd. (JP) 1998-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286093-A1 ANTI-INFLAMMATORY COMPOSITION CONTAINING DOCOSAHEXAENOYL LYSOPHOSPHATIDYLAMINE AS AN ACTIVE INGREDIENT ALOX5, PLA2G4A, PLA2G10 ELANE 123/4885ABCB1 4642/4885AKR1C3 1436/4885
US-20250082592-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 TFAM, RORA, CKMT1A; CKMT1B ELANE 4352/4885ABCB1 2190/4885AKR1C3 2163/4885
US-20020164351-A1 External compositions for skin comprising sphingoglycolipid UGCG, UGGT1, MAN1B1 ELANE 1695/4885ABCB1 4864/4885AKR1C3 357/4885
US-20100280231-A1 WHITENING AGENT COMPRISING EQUOL OR ITS SACCHARIDE DERIVATIVE AS AN EFFECTIVE INGREDIENT ENO1, GALE, UGGT1 ELANE 104/4885ABCB1 4262/4885AKR1C3 359/4885
US-20020006414-A1 EXTERNAL COMPOSITION FOR SKIN COMPRISING SPHINGOGLYCOLIPID UGCG, MAN2A1, GALK1 ELANE 604/4885ABCB1 4866/4885AKR1C3 382/4885
US-12221495-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide TSLP, NPR1, VIP ELANE 2286/4885ABCB1 3903/4885AKR1C3 3299/4885
US-12065512-B2 Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide TSLP, NPR1, VIP ELANE 2286/4885ABCB1 3903/4885AKR1C3 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.